Patient Guide: A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 165 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT03653507
Status: ACTIVE_NOT_RECRUITING
Condition: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase: PHASE3

Where You Can Participate

This study is available at 165 locations across the country.

Top locations include:
  • • Monterey, California
  • • Fairway, Kansas
  • • New Orleans, Louisiana
  • • And 162 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). - Join Clinical Trial NCTNCT03653507

How to Join This Clinical Trial - NCTNCT03653507

Learn how to participate in this PHASE3 trial studying an investigational therapy for Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT03653507 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 165 locations. Find a study site near you:

Clinical Research Site

Monterey, California 93940 - United States

Status: Contact for availability

Clinical Research Site

Fairway, Kansas 66205 - United States

Status: Contact for availability

Clinical Research Site

New Orleans, Louisiana 70121 - United States

Status: Contact for availability

Clinical Research Site

Albuquerque, New Mexico 87109 - United States

Status: Contact for availability

Clinical Research Site

New York, New York 10021 - United States

Status: Contact for availability

Clinical Research Site

The Bronx, New York 10467 - United States

Status: Contact for availability

Clinical Research Site

Boiling Springs, South Carolina 29316 - United States

Status: Contact for availability

Clinical Research Site

Dallas, Texas 75390 - United States

Status: Contact for availability

Clinical Research Site

Dallas, Texas 75390 - United States

Status: Contact for availability

Clinical Research Site

Houston, Texas 77030 - United States

Status: Contact for availability

And 155 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships